Biosimilar Firms Must Be Ready for US ‘Patent Dance,’ Says IP Lawyer
August 13, 2014
Dan Stanton
BioPharma-Reporter.com
Axinn counsel Stacie Ropka was quoted in Dan Stanton’s article, “Biosimilar Firms Must Be Ready for US ‘Patent Dance,’ Says IP Lawyer,” which appeared on BioPharma-Reporter.com.
Click here to access the article.